MidWest Drug Development Conference
ONLINE EVENT | Oct. 4-5, 2021
2021-10-04 08:00:00
Register!
Downloads
  • 2021 Program
  • Flyer
  • 2021 Schedule
  • 2019 Program
  • 2018 Program
  • Map & Other Info (Coming soon!)
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • Categories
    • Institutions
    • Startups
    • Previous Technologies
  • Sponsors
  • News
  • Contact

RNA-binding protein inhibitors slow tumor growth in metastatic cancers

University of Kansas

Despite recent therapeutic advances in cancer treatment, metastatic cancer remains the primary cause of cancer deaths. Metastatic cancer spreads from the primary site of the cancer’s origin, often a solid tumor, to other parts of the body. Although primary solid tumors can be effectively treated using local surgery or radiation, metastasis requires more systemic treatment and preventative regimens. As such, identification of new therapeutic targets and development of potent compounds are urgently needed to combat lethal metastatic cancers.

The present technology has identified novel compounds that inhibit the RNA-binding protein, Hu-antigen R (HuR). HuR is a major contributor to tumorigenesis, tumor growth, and metastasis. Furthermore, HuR overexpression can result in tumors developing a resistance to chemo- and radio-therapy. Accordingly, the HuR inhibitors of the present technology can be therapeutic agents for systemically preventing and treating metastasis as well as treating a variety of cancers, including breast cancer, colon cancer, prostate cancer, brain cancer, ovarian cancer, pancreatic cancer, and lung cancer.

Cytoplasmic binding of HuR to mRNA leads to mRNA stabilization and increased translation of proteins that have been implemented in cell proliferation, cell survival, angiogenesis, invasion, metastasis, and cancer treatment resistance. Novel compounds of the present technology bind to the RNA recognition motifs (RRM1/2) of the HuR protein, inhibiting HuR’s ability to bind to mRNA. By inhibiting formation of the HuR–mRNA binding complex, compounds of the present technology prevent transcriptional upregulation of oncogenic proteins Musashil (Msi1), Musashi2 (Msi2) and anti-apoptotic proteins, Bcl-2 and XIAP, which in turn inhibits Wnt/Notch activation. Accordingly, the HuR inhibitors of the present technology prevent downstream signaling events associated with tumor growth and metastasis by preventing HuR binding to mRNA.

Other developing treatments for metastatic cancer are toward mutation-specific therapies which can elicit tumor responses initially, but are short-lived as these therapies often select for the expansion of tumor subclones that harbor drug-resistance mutations. HuR inhibitors of the present technology specifically targets mRNA which encodes proteins involved in cancer treatment resistance. Hence, HuR inhibitors should not loose effectiveness overtime and combinations of HuR inhibitors with, for example, chemotherapy have a high chance to display synergistic effects and overcome chemoresistance.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
An Online Event
Oct. 4-5, 2021

Latest News
  • Presentation schedule set for 2021 September 21, 2021
  • MWDD moves to a virtual event in 2021 August 17, 2021
  • Sponsorship, presentation slots nearly full July 29, 2021
  • Registrations are now open for 2021 March 25, 2021
Twitter Hightlights
  • Today's the day!
    491 days ago
  • Schedule is set for the 2021 MidWest Drug Development Conference. Register today! https://t.co/5SvzL4EhuV
    504 days ago
  • No surprise to see some incredible innovations out of @UWMadison that could change drug delivery approaches, cancer… https://t.co/h90yfHwC5k
    505 days ago

Follow us! @DrugMw